Filing Flows › Comparisons › AMGN vs MRNA
Amgen vs Moderna: AMGN and MRNA compared
Amgen is the larger company: $10.4B of revenue in its latest quarter (Q3 2026) against $1.3B for Moderna (Q3 2026). Moderna is growing faster (+29% against +8% a year earlier). Amgen is more profitable, with an operating margin of 35.8% against 9.9%.
Where the money goes: AMGN and MRNA
Amgen (AMGN) · Q3 2026
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Moderna (MRNA) · Q3 2026
Moderna, Q3 2026: revenue $1.3B (+29% year over year), operating margin 9.9%, net earnings $162M, operating cash flow −$1.6B. The chart follows the revenue to costs, profit and cash.
| Amgen (AMGN) | Moderna (MRNA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.4B | $1.3B |
| Revenue growth, Y/Y | +8% | +29% |
| Operating margin | 35.8% | 9.9% |
| Net earnings | $3.9B | $162M |
| Net margin | 37.3% | 12.3% |
| Operating cash flow | $4.2B | −$1.6B |
| Free cash flow | $3.7B | — |
| Market value | $251.3B | $109.3B |
| P/E | 26.7× | — |
| Analysts’ mean target | $429.74 | $145.42 |
Where the revenue comes from
Amgen
- Product sales: $9.9B (95%)
- BLINCYTO: $496M (5%)
Moderna
- Net product sales: $1.3B (97%)
- RSV: $29.0M (2%)
- Collaboration Arrangement, Including Arrangements with Affiliate: $8.0M (1%)
Questions
Which is bigger, Amgen or Moderna?
Amgen is the larger company: $10.4B of revenue in its latest quarter (Q3 2026) against $1.3B for Moderna (Q3 2026).
Is Amgen or Moderna growing faster?
Moderna is growing faster (+29% against +8% a year earlier).
Which is more profitable, Amgen or Moderna?
Amgen is more profitable, with an operating margin of 35.8% against 9.9%.
More: Amgen earnings · how Amgen makes money · Moderna earnings · how Moderna makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.